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Abstract
Summary Using an electronic medical record (EMR)-based dashboard, this study explored osteoporosis care gaps in primary
care. Eighty-four physicians shared their practice activities related to bone mineral density testing, 10-year fracture risk calcu-
lation and treatment for those at high risk. Significant gaps in fracture risk calculation and osteoporosis management were
identified.
Purpose To identify care gaps in osteoporosis management focusing on Canadian clinical practice guidelines (CPG) related to
bone mineral density (BMD) testing, 10-year fracture risk calculation and treatment for those at high risk.
Methods The ADVANTAGE OP EMR tool consists of an interactive algorithm to facilitate assessment and management of fracture
risk using CPG. The FRAX® and Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tools were embedded to
facilitate 10-year fracture risk calculation. Physicians managed patients as clinically indicated but with EMR reminders of guideline
recommendations; participants shared practice level data on management activities after 18-month use of the tool.
Results Eighty-four physicians (54%) of 154 who agreed to participate in this study shared their aggregate practice activities.
Across all practices, there were 171,310 adult patients, 40 years of age and older, of whom 17,214 (10%) were at elevated risk for
fracture. Sixty-two percent of patients potentially at elevated risk for fractures did not have BMD testing completed; most
common reasons for this were intention to order BMD later (48%), physician belief that BMD was not required (15%) and
patient refusal (20%). For patients with BMD completed, fracture risk was calculated in 29%; 19% were at high risk, of whom
37% were not treated with osteoporosis medications as recommended by CPG.
Conclusion Despite access to CPG and fracture risk calculators through the ADVANTAGE OP EMR tool, significant gaps
remain in fracture risk calculation and osteoporosis management. Additional strategies are needed to address this clinical inertia
among family physicians.
Keywords Osteoporosis . Electronic medical record . Decision support tools . Care gaps
Introduction
Osteoporosis is treatable and fractures can be prevented [1].
However, it remains largely undiagnosed and untreated [2–4].
Fewer than 20% of women and 10% of men experiencing a
fragility fracture receive therapies to prevent further fractures
[2, 3, 5]. Canadian clinical practice guidelines (CPGs) for the
assessment andmanagement of osteoporosis specify that man-
agement should be guided by an assessment of patients’ ab-
solute risk of fractures [1]. Recommendations from these
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guidelines include, obtaining a history and physical examina-
tion to identify risk factors for falls and fractures that would
warrant further radiographic imaging, bone mineral density
(BMD testing), and calculation of 10-year risk of major oste-
oporotic fractures (i.e., fracture of the hip, clinical vertebra,
forearm or proximal humerus). Fracture risk assessment can
be conducted with either the Fracture Risk Assessment tool
(FRAX®) [6] or the Canadian Association of Radiologists
and Osteoporosis Canada (CAROC) absolute fracture risk as-
sessment [7]. Those deemed at high risk should be considered
for both pharmacological (antiresorptive agents, bone-
forming agents, calcium and vitamin D supplementation)
and non-pharmacological (exercise, falls prevention, smoking
cessation) interventions [1]. The use of FRAX® has been
included in many osteoporosis CPGs to facilitate osteoporosis
case-finding and treatment decisions [1, 8–10]. Despite the
availability of fracture risk assessment tools and advances in
pharmacological therapies, osteoporosis continues to be
underdiagnosed and undertreated [11–13]. Barriers to the
use of osteoporosis CPG include clinician uncertainty about
fracture risk assessment, lack of clinical protocols and organi-
zational processes to support use of best practices [11, 14, 15],
concerns about medication side effects [16, 17], and lack of
knowledge on medication use (drug holidays, when to stop)
[11]. Fracture liaison services have been demonstrated to im-
prove communication, management, and outcomes; however,
these discharge coordination initiatives are rare in Canadian
hospitals [18]. Much of the research on improving treatment
in osteoporosis has focused on interventions in specialized
fracture clinics [18], but very little has been conducted at the
primary care level. Family physicians have identified a need
for clinical support tools that identify potential risk factors,
calculate fracture risk, and advice on treatment options [19].
In a study of 1054 family physicians in Ontario, 77% identi-
fied the lack of electronic medical record (EMR) tools as a
significant barrier to implementing the osteoporosis CPG [20].
The absence of EMR reminders and recalls for medications
requiring regularly scheduled injections has been identified as
decreasing adherence and causing discontinuation [11].
There is evidence in the literature that clinical decision
support systems that integrate decision support tools within
EMR software can improve care processes and health out-
comes [21–23]. A review of research on EMR dashboards
found that they provide a significant opportunity for efficient-
ly and accurately gathering and processing patient data and
improving quality of care [24]. A proof of concept study on an
EMR quality dashboard focused on 17 health care clinical
indicators, not including osteoporosis, found that within 90
days of training, documentation (coding) of patient diagnoses
(diabetes, hypertension), screening results (colorectal cancer,
breast cancer), and smoking and body mass index status in-
creased by up to 4% [25]. Similar quality improvements were
found with the use of a diabetes-specific EMR dashboard [26].
Consistent with these types of dashboards and building on the
identified needs of Canadian family physicians for more edu-
cation on the assessment and management of osteoporosis and
their desire for EMR-based tools to support guideline imple-
mentation [20], we developed the Dashboard Initiative for
Quality Improvement in the Management of Patients with
Osteoporosis (ADVANTAGE OP). The ADVANTAGE OP
dashboard serves as a mechanism for alerting physicians of
patients’ potential fracture risk to improve screening and man-
agement. In this study, we used this EMR-based osteoporosis
decision-support tool to identify potential care gaps in the
implementation of best practice recommendations in patients
with or at risk for fracture and assess the management of these
patients by Canadian primary care physicians.
Methods
Participants
A convenience sample of two-hundred family physicians
practicing across Canada whose practice used Telus PS
Suite and MedAccess EMR platforms were invited to partic-
ipate in this study. Telus also advertised recruitment for this
study in their corporate newsletter and other educational fo-
rums. The most common EMR vendor is Telus EMR plat-
forms in Ontario and to a lesser extent British Columbia and
Alberta. Participants were required to use the ADVANTAGE
OP EMR dashboard for a period of 18 months (July 31st,
2018–December 31, 2019) to share practice level EMR data
(not patient level data) and where relevant provide the reasons
why management differed from that recommended in
Canadian CPGs. At the end of the 18-month time period,
participants’ practice level data were downloaded for analysis.
Participants receivedmonetary compensation (fair market val-
ue honorarium) to use the ADVANTAGE OP dashboard to
review their practice-related osteoporosis assessment and
management; it was anticipated that total time commitment
in this study would be a minimum of 12 h.
Electronic medical record dashboard
Participants completed an educational session, which included
an introduction to the osteoporosis and falls custom EMR tool
[27] and instruction on how to use the ADVANTAGE OP
EMR dashboard. Participants also had access to a study spe-
cific protocol that contained educational resources on risk as-
sessment and osteoporosis management, including Canadian
CPGs. The ADVANTGE OP EMR dashboard is an interac-
tive algorithm designed to facilitate the use of evidence-based
management strategies related to: (1) BMD testing for patients
potentially at high risk, (2) fracture risk assessment, and (3)
appropriate utilization of pharmacological therapy based on
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Canadian osteoporosis CPGs [1]. Consistent with the
Canadian osteoporosis CPGs, patients were deemed as poten-
tially at high risk for fracture when any of the following
criteria are met: (1) all females, age ≥70 years, (2) age ≥50
years with any of the following criteria documented: fracture
of the proximal humerus, wrist, vertebral, pelvis, or femur, or,
(3) femoral neck or lumbar spine t-score less than or equal to
−2.5 [7].
The EMR dashboard consisted of four steps that users
proceeded through; these steps are summarized in Fig. 1.
Within the EMR dashboard, patients within each partici-
pants’ practice with osteoporosis and fractures were iden-
tified based on Systematized Nomenclature of Medicine
Clinical Terms (SNOMEDCT) code 64859006 or
International Classification of Disease 9 (ICD-9) codes
for fracture or osteoporosis [28], BMD T-scores (≤2.5),
high 10-year fracture risk according to FRAX® (≥20%
or ≥3% hip fracture risk) or CAROC (Step 1). To ensure
all relevant patients were included in the dataset, those
patients who had a prior fracture or potentially having a
history of osteoporosis, but who did not have this listed in
the EMR problem list were identified for physicians to
determine if they met ICD-9 criteria for fracture or oste-
oporosis codes. Participants were asked whether they
would like to request BMD testing for patients potentially
at high risk for fractures, including those at high risk who
are on treatment and require annual BMD testing and
those at moderate risk on treatment who require BMD
testing every three years. When it was decided not to
order BMD testing, participants were asked to provide a
reason for their management decision from the following:
patient refusal, not easily accessible/available in my prac-
tice area, prior BMD was normal/low risk, do not believe
BMD is required, would like specialist referral for BMD,
referred for BMD/awaiting results, or, will refer for BMD
soon. Physicians were able to select more than one reason
for why BMD was not ordered (Step 2). Patients with
available BMD test results but for whom 10-year risk of
fracture was not yet calculated were identified and for
each patient, participants were asked to calculate the in-
dividual’s fracture risk using FRAX® or CAROC, both of
which are embedded in the dashboard (Step 3). Patients
identified at high risk for fracture based on fracture risk
calculations with no prescribed fracture prevention medi-
ca t ions (e .g . , b i sphosphonates , denosumab, o r
teriparatide) were identified and participants were asked
if they would treat them based on CPGs and if not, pro-
vide a reason for their management decision from a spec-
ified list of reasons: patient refusal, social reason (cost,
access), medical reason (side effects, intolerance, comor-
bid conditions), specialist prescribed treatment plan, belief
that no treatment was the most appropriate plan, disagree-
ment with recommendation, lack of comfort with making
treatment changes, or, intentions to modify the treatment
plan (Step 4). Physicians were able to select more than
one reason for this management decision. The list of ther-
apies in the dashboard was complete for those medica-
tions available based on provincial drug plans and most
frequently used in Canada for fracture prevention.
Outcome measures
The primary outcome measures were: (1) proportion of pa-
tients potentially at high risk for fractures based on study
criteria for whom BMD testing was not completed and rea-
sons why, (2) proportion of patients for whom BMD testing
was completed but T-score was not documented, and (3) the
proportion of patients at known high risk for fractures based
on CAROC or FRAX® who were not treated according the
osteoporosis CPG [1].
Statistical analysis
Patient counts for each participant were calculated automati-
cally within the Telus system for each of the four steps within
the dashboard and downloaded as aggregated across all par-
ticipants in an excel.csv format. Descriptive analysis of each
metric was reported using frequency and percentage. All anal-
ysis was performed using SAS 9.4 software (SAS Institute,
NC, USA).
Results
A total of 154 physicians agreed to participate in this study; 84
(54.5%) shared their practice activities using the dashboard.
Of the participants who shared their practice data, the majority
were from Ontario (N = 51; 60.7%). The remaining partici-
pants were from British Columbia (N = 17; 20.2%), Alberta
(N = 9; 10.7%), Nova Scotia (N = 6; 7.1%) and Saskatchewan
(N = 1; 1.2%).
A summary flow chart of the dashboard results is presented
in Fig. 2. Among the total patient population (171,310) across
all participants (N = 84), 8,158 patients were identified in Step
1 as needing to be coded with osteoporosis or fracture in the
EMR problem list; 66.8% (N = 5,446) of whom had osteopo-
rosis based on documented ICD-9 733 or with SNOMEDCT
code 64859006. Physicians were asked to review the files of
2,712 (33.2%) patients, who potentially could have osteopo-
rosis but who were not coded as such. Some of these patients
(17.8%, n = 482) had risk scores (based on FRAX® or
CAROC) of equal to or greater than 20% but were not coded
as having osteoporosis. Others had BMD T-scores ≤2.5
(2.8%, n = 75), a diagnosis of osteoporosis listed in two or
more physician reimbursement codes (23.9%, n = 648), or
osteoporosis documented as text (23.9%, n = 647) but were
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STEP 1: Code Your Osteoporosis and Fracture Patients
Purpose: To identify patients with or at risk for fractures, so that they can be coded and 
reliably identified in the dashboard. 
Response Generated by Dashboard: Patients are categorized as: having a prior fracture, 
potentially having a history of osteoporosis, not coded in the problem list, potentially having 
osteoporosis based on BMD T-score 2.5,  fracture risk score (FRAX or CAROC) >10% or 
based on osteoporosis diagnosis physician reimbursement codes, or as having osteoporosis 
based on documented diagnostic codes.
Expected Physician Response
Review patients who potentially have osteoporosis but who are not coded in the problem list; 
update problem field as relevant. Determine if patients with osteoporosis previously coded are 
active or inactive (no longer part of practice).
STEP 2. Heightened Need for BMD Screening
Purpose: to identify patients that are potentially at high risk for osteoporosis requiring BMD 
screening.
Response Generated by Dashboard: Patients potentially at risk but who do not have a BMD 
report or T-score documented are identified.
Expected Physician Response
Review patient records to determine if BMD is required, or to enter BMD T-scores if available 
but not documented. When BMD is required, physicians are to recall patients to order BMD or 
provide a reason for not ordering BMD.
STEP 3. Calculate 10-year Fracture Risk in Patients with BMD Completed
Purpose: to identify 10-year fracture risk using CAROC or FRAX for patients with 
osteoporosis coded or identified potentially at risk with BMD completed, but who do not have 
a 10-year fracture risk documented. 
Response Generated By Dashboard: Patients are categorized as being at low, moderate or 
high risk for fractures, or as not having a documented risk score.
Expected Physician Response
Review patients with osteoporosis coded or heightened need (Age 65 with risk factors) for 
risk score with BMD completed to either calculate fracture risk with CAROC or FRAX or 
provide a reason for their management decision.
STEP 4: Medication Review
Purpose: to identify high risk patients without medication prescribed to conduct a review. 
Response Generated by Dashboard: Patients with a most recent 10-year fracture risk score of 
20 (CAROC or FRAX) are categorized as being on treatment (bisphosphonates, denosumab, 
teriparatide), no treatment documented, or not currently on treatment but a reason provided. 
Expected Physician Response
Review all patients listed as being at high risk with no medication documented to either recall 
patients for treatment change or decide no medication treatment is appropriate; when 
medication is not prescribed select a reason for this from a list of response choices.
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not coded as having osteoporosis. Similarly, 31.7% of patients
(n = 860) had a fracture documented as text, but were not
coded as having had a fracture.
Heightened need for BMD testing
Among the whole patient population (171,310), a total of
17,214 (10%) patients were identified as potentially at
high risk for fractures, the majority of whom (61.6%, n
= 10,607) did not have completed BMD testing whereas
34.2% (n = 5,882) did (Figs. 2 and 3). Among patients
potentially at high risk for fracture with completed BMD
testing (N = 5,882), only 26.5% (n = 1,558) of patients
had their T-scores documented within their EMR. Of
those patients identified as potentially at risk for fractures
(N = 17,214), a relatively small proportion (4.2%, n =
725) had a reason listed for why BMD testing was not
completed. Fig. 4 presents the reasons physicians provid-
ed for why BMD testing was not completed for patients
potentially at high risk; the most common being patient
refusal in 19.6% (n = 209) and 47.8% (n = 509) indicating
intentions to order BMD testing. BMD testing by age is
Fig. 1 Summary description of the ADVANTAGE OP electronic
medical record dashboard
CAROC, Canadian Association of Radiologists and Osteoporosis
Canada; FRAX®, Fracture Risk Assessment tool
Total patient population
N = 171,310
Step One: Coding patients for osteoporosis or fractures
Patients requiring coding 
N = 8158
Documented osteoporosis based 
ICD or SNOMED codes*
N = 5,446 (66.8%)
Not coded but potential 
osteoporosis
N = 2,712 (33.2%)
Reason for no BMD provided
N = 725 (4.2%)
No 10-year fracture risk 
score calculated
N = 5,531 (70.0%)
Completed BMD
N = 5,882 (34.2%)
No completed BMD testing 
N=10,607 (61.6%)
Step Two: Heightened Need for BMD Testing
Potentially at high risk for fractures 
N = 17,214
Step Three: 10-year fracture risk in patients with 
completed BMD Testing
Completed BMD regardless of risk status
N = 7,901
Reason for no risk score 
provided
N = 55 (0.7%)
10-year fracture risk 
calculated
N = 2,315 (29.3%)
Low risk
N = 759 (32.8%)
Moderate risk
N = 1,109 (47.9%)
High risk
N = 447 (19.3%)
Prescribed osteoporosis 
medications
N = 289 (63.4%)
Not prescribed 
osteoporosis medications
N = 167 (36.6%)
Step Four: Medication review for those at high risk
N = 456**
Fig. 2 Summary flow chart of
the dashboard results. BMD,
Bone Mineral Density
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shown in Fig. 5. In almost 75% (n = 35,308) of patients
65 years of age and older, BMD testing was not
completed.
10-year Fracture risk in patients with BMD
Among all patients with completed BMD screening (N =
7901; regardless of risk status for fractures), risk scores were
calculated using FRAX® or CAROC in 29.3% (n = 2,315) of
patients; 70.0% (n = 5,531) of patients did not have risk scores
calculated and 0.7% (n = 55) had a reason listed for why a
fracture risk score was not calculated. Among those with cal-
culated risk scores (N = 2,315), 19.3% (n = 447) were at high
fracture risk; 32.8% (n = 759) were at low risk and 47.9% (n =
1,109) were at moderate risk.
Medication review
Among those at high fracture risk (N = 456), 63.4% (n = 289)
were on medications for osteoporosis (n = 167 on
bisphosphonates; n = 122 on denosumab). The most common
reason for non-treatment was the belief that this was appropri-
ate (44.4%, n = 115); in 9.7% of cases (n = 25), the physician
intended to modify the treatment plan (Fig. 6). Other reasons
included patient refusal, social or medical reasons, a specialist
made treatment decisions, disagreement with recommenda-
tions and lack of comfort in making treatment changes.
Discussion
Despite evidence that interventions combining education and
EMR-based alerting systems can increase BMD screening and
appropriate osteoporosis medication prescribing [29], in this
study, there continued to be a significant number of patients at
risk who were not screened or treated.
Point-of-practice tools including algorithms and checklists,
and integration of decision support tools into EMRs have been
identified as strategies for supporting CPG implementation
[30]. Alerting systems appear to be key to facilitating practice
change. A study examining the use of an osteoporosis order
set embedded within an EMR found that while it increased the
prescribing of calcium, it had minimal impact on the prescrib-
ing of osteoporosis medication; these findings were attributed,
in part, to the lack of an alerting or reminder function [31].
While physicians value point-of-practice tools and have iden-
tified a desire more EMR-based tools to facilitate clinical de-
cision making, the fact exists that these tools create an extra
layer to their work flow. Tool complexity, lack of time to
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BMD done, T-score not
documented* (N = 4,324)
BMD not done
(N = 10,607)
BMD not done, reason










Fig. 3 Status of BMD screening
among patients identified














































Fig. 4 Barriers for ordering BMD
for patients potentially at risk (N =
1065)*
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and financial disincentives have been identified as barriers to
using these types of tools in clinical practice [20]. In this
study, fracture risk scores were only calculated in 29% of
patients with completed BMD screening. In a qualitative study
of physicians’ views of osteoporosis management, physicians
reported that their limited use of the FRAX® tool for calcu-
lating fracture risk was because the FRAX® was not embed-
ded into the EMR [32]. Intuitively it makes sense that the extra
step of accessing FRAX® online would be barrier; however,
in the current study, FRAX® and CAROC were embedded
within the dashboard for immediate access. Other strategies
are needed to facilitate their use. The development of tools that
self-populate with existing information within the EMR (pas-
sive data collection) may address barriers related to time con-
straints and the performance of extra steps to ascertain results
to better identify those at risk for fractures [33, 34]. Moreover,
it has been suggested that combined education and decision
support tools aimed at both physicians and patients may be
effective for osteoporosis management [35].
This study highlights significant care gaps in the assess-
ment and management of osteoporosis, despite the use of an
EMR-based dashboard to improve treatment. Only a third of
those potentially at high risk for fractures had BMD testing
completed, and among all patients with BMD completed, only
a third had 10-year fracture risk scores documented. Among
those with high 10-year fracture risk scores, a third were not
on treatment. These findings are consistent with other studies
that have found that, despite the prevalence of fragility frac-
tures, there remains a considerable care gap [2, 3, 36, 37]. The
lack of treatment following a fracture is in sharp contrast to
other conditions where one medical event is predictive of sub-
sequent events, such as acute myocardial infarction after
which 96% of patients are prescribed beta-blockers and 98%
aspirin to prevent subsequent events [38]. We found that a
high proportion of physicians indicated intentions to order
BMD testing “soon”, the fact remains that they did not order
the testing when first alerted to potential risk. When physi-
cians did order BMD testing, the resulting T-scores were often
not documented, preventing a potential alert for calculating
fracture risk. Challenges into the integration and usability into
workflow included osteoporosis and fractures were not well
coded/documented in the EMR with ICD codes that identify
fractures and osteoporosis, and BMD reports not automatical-
ly populating the EMR [39].
Forty-four percent of physicians indicated that they were
not prescribing medication to patients at high risk of fracture
because they believed their current care plan for their patients
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Fig. 5 Need for BMD screening
among all patients at risk for








































Fig. 6 Reasons provided for non-
treatment in high risk patients (N
= 259)*
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treatment plan contrary to CPG would be appropriate.
Potential adverse effects, particularly as related to potential
atypical femur fractures associated with bisphosphonate use,
scepticism about treatment efficacy, and a perceived lack of
urgency for treating osteoporosis have recently been identified
as reasons for not prescribing osteoporosis medications [11,
12, 16]. Further research is needed to better understand why
physicians choose not to treat patients for osteoporosis and
how this might best be mediated, particularly with education
aimed at addressing negative physician attitudes and beliefs
towards osteoporosis treatment. There may be factors related
to comorbid conditions, such as a desire to minimize
polypharmacy or physician attitudes towards osteoporosis
and fracture prevention. There is some evidence that physi-
cians believe that osteoporosis is not as much of a priority to
treat in comparison to other conditions such as diabetes, car-
diovascular disease and hypertension [32, 40]. Organizational
support may be an additional factor facilitating the implemen-
tation CPG and point-of-practice tools [41–43]. As physicians
in this current study were recruited individually, not at a prac-
tice setting level, the role of organizational support and pro-
motion in using the Advantage OP dashboard is not known.
Further research is needed to understand the role that organi-
zational support and environmental context play in facilitating
the use of the dashboard.
Limitations
Participants in this study were self-selected and thus selection
biasmay impact the generalizability of our findings. The dash-
board did not include raloxifene and hormone therapy as anti-
fracture therapies, which may have resulted in an underesti-
mation of patients receiving some fracture protection.
However, while these medications are both available in
Canada, utilization in Canada and other countries for osteopo-
rosis is low and thus it was decided not to include them in the
dashboard [44, 45]. As practice level data were collected, the
absence of patient level data limits our understanding of the
decisions made about the BMD screening and treatment.
While 447 patients were deemed at high risk for fractures
based on 10-year fracture risk calculations, information on
the management of 456 patients was generated. At the time
that physicians shared their practice information at study end,
there were 25 cases in which they intended to modify the
patients’ treatment plan; information on whether this occurred
is not available. In total, 7,901 patients had BMD testing com-
pleted regardless of risk status. While it is not entirely clear
why patients at low risk were completing BMD testing and
some at high risk were not being tested, this could reflect that
some patients may have completed BMD testing over the age
of 65 who were not at risk, consistent with CPGs [1]. The
collection of practice level data also does not allow us to fully
understand changes in observations, which may result when
patients leave and new patients enter a practice or their health
status changes as classified by their physician. A high propor-
tion of participants (46%) did not share their practice data. It
has been suggested that this might be due to perceptions that it
involved too much time for the amount of work and compen-
sation provided or, because this was new learning for some
physicians, they were unsure of how to “share” data and may
have been uncomfortable with sharing their data. It has also
been suggested that as use of the dashboard requires a staff
member to execute patient recalls, limited health human re-
sources may have limited use of the dashboard. Following the
study time period, we surveyed participants to gather informa-
tion about their practice model and to assess their perceptions
of their use of this tool including perceived helpfulness in
calculating 10-year fracture risk and assessing and managing
patients at heightened risk for fractures, feasibility of use,
identification of potential barriers to utilizing the tool as part
of routine clinical practice and likelihood of continued use of
the tool. In particular, we were interested in identifying the
barriers to use by those physicians who had initially agreed to
participate but failed to use the tool. Unfortunately, the re-
sponse rate to this survey was less than 10%, so we are unable
to provide a greater understanding of the continued clinical
inertia in osteoporosis diagnosis and management. We
attempted to gather some of this information as part of presen-
tations that we conducted to share study results with partici-
pants. A facilitated discussion followed, asking for facilitators
and barriers to treatment of osteoporosis. Identified facilitating
factors included having the guidelines embedded in the EMR
tool and including questions on risk factors for FRAX®.
Barriers included the following: having to input bone mineral
density values into the EMR form, the EMR tool not automat-
ically calculating the FRAX® score, and not being familiar
with FRAX® as the majority of radiologists report using
CAROC.
Future studies will need to better understand the barriers to
using this type of clinical practice tool and potential changes
and strategies needed to improve use of the dashboard. For
example, there may be opportunities to increase use of the
dashboard by involving primary care nurses in its use.
Nurses could maintain documentation on patients experienc-
ing a fracture or having been diagnosed with osteoporosis
(Step 1 in the dashboard process), flagging those requiring
BMD testing (Step 2) and then flagging those requiring frac-
ture risk assessment to family physicians.
This was an observational study. More rigorous methodol-
ogies, including randomized controlled trials comparing the
use of the Advantage OP dashboard with usual care will in-
crease our understanding of the impact associated with this
EMR tool. Further research is needed to better understand
perceptions of the Advantage OP dashboard and opportunities
to improve and sustain usage.
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Conclusion
Despite the use of an EMR decision support tool for osteopo-
rosis, there continues to be significant gaps in BMD testing,
fracture risk calculation and management among high risk
patients, suggesting that additional knowledge translation
strategies are needed to improve both osteoporosis screening
and care. A better understanding of physician interface with
EMR decision support tools as well as patient decision-
making is needed to inform the development of strategies
and tools that will better support the implementation of oste-
oporosis CPG. Point-of-practice and decision support tools,
including those embedded within EMR platforms, should be
utilized to address existing knowledge and action (practice)
gaps and will need to include functions beyond alerting and
reminders to support CPG implementation.
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